Research programme: ulcerative colitis therapeutics - Warner Chilcott

Drug Profile

Research programme: ulcerative colitis therapeutics - Warner Chilcott

Latest Information Update: 18 Dec 2013

Price : $50

At a glance

  • Originator Warner Chilcott
  • Developer Actavis Inc
  • Class Aminosalicylic acids; Small molecules
  • Mechanism of Action Lipoxygenase-cyclooxygenase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Ulcerative colitis

Most Recent Events

  • 18 Dec 2013 No development reported - Preclinical for Ulcerative colitis in USA (unspecified route)
  • 01 Oct 2013 Warner Chilcott has been acquired and merged into Actavis Inc
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top